Young David 4

What Happened

• David Young, President of Research & Development and a director at Processa Pharmaceuticals (PCSA), purchased 1,545 shares on 2026-04-15. The transaction was an open-market/private purchase (Form 4 code P) at $2.97 per share, for a total reported value of $4,589. This was an acquisition (purchase), which is generally viewed as a more bullish signal than a sale, though the dollar amount here is modest.

Key Details

• Transaction date and price: 2026-04-15 — 1,545 shares at $2.97 each.
• Total value: $4,589.
• Transaction type: Purchase (code P) — open market or private purchase as reported.
• Shares owned after the transaction: Not specified in the information provided in this summary (check the Form 4 for the exact post-transaction holdings).
• Filing date: 2026-04-17 — filed two days after the transaction, which appears timely under Form 4 reporting rules.
• No 10b5-1 plan, tax-withholding, or other footnotes were disclosed in the summary provided.

Context

• Small-dollar insider purchases (like this ~$4.6k buy) can indicate confidence but are limited in scale; they are more informative when seen alongside prior trades or changes in insider ownership. Retail investors may want to watch for larger or repeated purchases by the same insider or look at overall insider activity for fuller context.